Form 4: NMSIC Co-Investment Fund Sells 350,000 Shares of Exagen Inc.

NMSIC Co-Investment Fund, L.P. reports the sale of 350,000 shares of Exagen Inc. common stock at $3.3 per share on March 25, 2025.

Summary

• On March 25, 2025, NMSIC Co-Investment Fund, L.P. sold 350,000 shares of Exagen Inc. common stock.
• The sale price was $3.3 per share.
• Following the transaction, NMSIC Co-Investment Fund, L.P. indirectly owns 1,758,958 shares.
• Sun Mountain Capital Partners LLC is the general partner of NMSIC.
• Brian Birk, Sally Coming, and Lee Rand are the controlling members of Sun Mountain Capital Partners LLC.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. A large shareholder selling shares can be interpreted negatively by the market, but without further context, it's difficult to assess the full impact.

Negatives

• NMSIC Co-Investment Fund, L.P. has decreased its holdings in Exagen Inc. by selling 350,000 shares.

Risks

• The sale of a significant number of shares by a major shareholder like NMSIC Co-Investment Fund, L.P. could potentially exert downward pressure on the stock price of Exagen Inc.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell the company's stock. These filings provide transparency into the transactions of those with privileged information and can influence investor sentiment.

Stakeholder Impact

• Shareholders may react to the sale of shares by NMSIC Co-Investment Fund, L.P., potentially impacting the stock price.
• The sale could influence investor confidence in Exagen Inc.

Key Dates

Keywords

Exagen Inc., NMSIC Co-Investment Fund, Sun Mountain Capital Partners, share sale, Form 4, beneficial ownership, XGN